🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Jon Trent, MD, PhD Sylvester Comprehensive Cancer Center William Tap Richard Riedel @DenverSarcomaMD Great discussion - we were honored to have you in to talk about the complexity of soft tissue sarcoma! #scmsm

The #Sarcoma Patient Education Conference at Duke University takes place Sat., Sept. 8 from 10:00 am to 3:00 pm. There is no cost to attend, so make sure you reserve your spot by signing up now! Note: Online regis. closes on Weds., Sept. 5. curesarcoma.org/event/patient-… #CureSarcoma

Wishing Duke Oncology a great #Sarcoma Education Day on Sept 7 & Fundraiser on Sept 8 - Strike Out for Sarcoma! Duke, we are thrilled the RIS, Sarcoma Patient Starter Notebook is a solid educational resource for newly diagnosed patients. Stronger Together! #SarcomaAwareness

#FDAODAC votes 11-0 in favor of the question: Does the demonstrated benefit of tazemetostat outweigh the risks of the drug in the proposed indication? (treatment of adult patients with metastatic or locally advanced epithelioid sarcoma who are not eligible for curative surgery)

.Sarcoma Foundation of America ODAC meeting voting results on question 2. The panel agrees that the benefits outweigh the risks for tazemetostat. A potential new treatment for patients with #epithelioidsarcoma. #sarcoma #curesarcoma

FDA Panel Supports Tazemetostat for Epithelioid Sarcoma onclive.com/web-exclusives…

.U.S. FDA advisory committee unanimously supports approval of tazemetostat @EpizymeRx for epithelioid sarcoma healio.com/hematology-onc…

Here's a good explanation of why the committee approved #tazemetostat for #epithelioid #sarcoma, including comments from Richard Riedel.

Today, we received U.S. FDA approval for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (#GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Learn more: bit.ly/2R0aKyZ

RIP Eddie Van Halen. Greatest rock guitarist of all time. Left a lasting impression on me in 1984 that has stuck with me ever since.

As the presidential election wraps up, time to head to the ASCO election! 1st up, Dr. #JimAbbruzzese for ASCO president. Jim has worked tirelessly for #pancreaticcancer, headed GI group @MDAndersonnews, now Duke Cancer med onc division chief. A thoughtful leader who listens.

We are so excited to welcome Joyce Hwang Andrew M. Peseski, DO Fahmin Basher, MD, PhD Drs. Kathrine DiNardo, Cameron Oswalt, Grayce Selig, and Cameron Wood to the Duke Heme/Onc Fellowship Program! We are so excited to have you join our wards and clinics in July 2021! Duke Cancer Duke Department of Medicine

We want to continue helping patients find expert care. Your donations help ensure that #ErdheimChester patients can access the care they deserve, no matter where they live. fundECD.org #endECD #ECDcare #EOY2020

broadinstitute.org/news/map-shows…

JUST RELEASED: In this episode of #OncLiveOnAir Richard Riedel Duke Cancer & Brian Van Tine Siteman Cancer Center discuss the multidisciplinary management of patients w/ sarcoma, the clinical impact of the U.S. FDA approval of ripretinib in the GIST paradigm. #scmsm ow.ly/UP3k50EBdie

It’s the last week of #SaromaAwarenessMonth & time to meet amazing two doctors, Richard Riedel and Breelyn Wilky, MD 🎗, who are leaders in the treatment of giant cell tumor of the bone (#GCTB) and/or tenosynovial giant cell tumor (#TGCT). Thank you both 🙌🏻 Read below:

FDA Approves Nab-Sirolimus for Advanced Malignant PEComa targetedonc.com/view/fda-appro… via Targeted Oncology

There are more than 100 types of cancer. Here's an overview of soft tissue sarcoma: 1.usa.gov/1Ph8hry